Annual Meeting

The AACR’s Annual Meeting is one of the largest and most important annual gatherings of scientists engaged in cancer research worldwide. The next Annual Meeting will take place in New Orleans, LA, March 28–April 1, 1998. The Chairperson of the Annual Meeting is Frank J. Rauscher III of the Wistar Institute. The Program Committee will invite outstanding scientists in the field to organize plenary sessions, symposia, controversy sessions, and meet-the-expert sunrise sessions. They also look forward to receiving for consideration for presentation the proffered papers submitted by members of the cancer research community. All abstracts must be sponsored by an AACR member in good standing. The deadline for receipt of abstracts in the AACR office was October 28, 1997.

AACR Minority Scholar Awards in Cancer Research Supported by the National Cancer Institute (CMBP)

Funds are being provided through the Comprehensive Minority Biomedical Program of the National Cancer Institute for the travel of a limited number of minority students to the 1998 AACR Annual Meeting. Eligible scientists are full-time predoctoral students, postdoctoral fellows, and physicians-in-training in the early stages of their careers who are either engaged in cancer research or who have training that could lead to contributions in this field. This travel award program applies only to minority groups that have been defined by the National Cancer Institute as being traditionally underrepresented in cancer research; these groups are Native Americans, African Americans, Hispanic Americans, Alaskan Americans, and Native Pacific Islanders. Only citizens of the United States and Canada or scientists who are permanent residents in those countries may receive one of these awards.

Although preference will be shown to authors of abstracts that have been accepted for presentation at the annual meeting, this is not a requirement for the award. Preference will also be given to new applicants. Awardees will be selected on the basis of their qualifications, references from mentors, and an estimation of the potential professional benefit to the Awardees. An advisory committee consisting of members of the AACR will review submitted applications and letters of reference. The award will consist of partial support of registration, travel, and subsistence expenses incurred in connection with attendance at the annual meeting.

Gertrude B. Elion Cancer Research Award

Application forms for the AACR’s 1998 Gertrude B. Elion Cancer Research Award, supported by an educational grant from Glaxo Wellcome Oncology, will soon be available. This one-year, $30,000 grant to a nontenured Assistant Professor supports meritorious basic, clinical, or translational research in cancer causation, prevention, or treatment. Tenured faculty in academia, federal government employees, and employees of pharmaceutical companies are not eligible for this award. Information and application forms will be mailed to AACR members and to those who requested application materials in the past as soon as they are available. Nonmembers who have not previously requested information or who have changed addresses should request information and application forms from the AACR Office.

AACR Research Fellowships

In 1998, the AACR will offer an enhanced program of sponsored fellowships for clinical and postdoctoral fellows. The basic, clinical, translational, and prevention fellowships will offer salary support at the level of $30,000 per year, with some fellowships extending for a term of two years. Eligibility has been expanded to include all citizens and permanent residents of any country in the Americas, who have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Medical residents, employees of industry, fellows with sponsorship for a similar program for the award year, and permanent employees of the federal government are not eligible. All Active, Corresponding, and Associate AACR members in the Americas will receive information and application forms by mail in the early Fall. Nonmembers may request information and application forms from the AACR Office. The deadline for applications will be early 1998, with the commencement of the award year on July 1, 1998.

AACR Special Conferences in Cancer Research

A number of meetings are now being organized in the AACR’s series of smaller scientific meetings. Following are some of the dates, locations, and organizing committees for these meetings. When full details of each meeting are available, AACR members will be the first to receive complete brochures and application forms for participation in these important conferences. Nonmembers may receive this information by sending their names and addresses to: Meetings Mail- ing List, AACR, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Up-to-date program information is also available via the Internet at AACR’s website (http://www.aacr.org/confrnc.tm1).

January 9–13, 1998
Molecular Mechanisms of Apoptosis Regulation
Chairpersons:
JOHN C. REED, La Jolla, CA
VISHVA M. DIXIT, S. San Francisco, CA
Renaissance Esmerelda Resort, Palm Springs, CA

January 24–28, 1998
Angiogenesis and Cancer
Chairpersons:
JUDAH FOLKMAN, Boston, MA
MICHAEL KLAGSBRUN, Boston, MA
Hyatt Orlando, Orlando, FL

June 14–18, 1998
Proteases and Protease Inhibitors in Cancer
Co-sponsored by the Danish Society for Pathology
Chairpersons:
KELD DAMO, Copenhagen, Denmark
HENRI ROCHEPORT, Montpellier, France
LYNN M. MATRISIAN, Nashville, TN
NILS BRUNNER, Copenhagen, Denmark
Nyborg Strand Conference Center, Nyborg, Denmark

October 14–18, 1998
Gene Regulation and Cancer
(10th Anniversary of AACR Special Conferences in Cancer Research)
Chairpersons:
PHILLIP A. SHARP, Cambridge, MA
STEVEN L. MCKNIGHT, Dallas, TX
The Homestead, Hot Springs, VA

December 2–6, 1998
Basic and Clinical Aspects of Prostate Cancer
Chairpersons to be Announced
Hyatt Grand Champions Resort, Indian Wells (Palm Springs), CA
Instructions for Authors

Scope
Clinical Cancer Research, a journal of the American Association for Cancer Research, publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Its focus is on innovative clinical research and translational research which bridges the laboratory and the clinic. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer; research on molecular abnormalities that predict incidence, response to therapy, and outcome; and laboratory studies of new drugs and biological agents that will lead to clinical trials in patients.

Specific areas of interest include clinical and translational research in: molecular pharmacology and chemotherapy; drug sensitivity and resistance; tumor immunology and immunotherapy; radiobiology and radiation oncology; solid tumor oncology; hematological malignancies; surgical oncology; pediatric oncology; molecular oncology and cancer genes; pathology, markers, and prognostic indicators; growth factors, cytokines, and signal transduction; bone marrow transplantation; gene therapy; cancer endocrinology; cell adhesion, invasion, and metastasis; prevention of primary and recurrent cancer; differentiation and cell death; clinical genetics; and detection of minimal disease.

Editorial Policy
When a manuscript is received for consideration, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission. The signature of the corresponding author on the letter of submission signifies that these conditions have been fulfilled.

Journal policy requires that authors, reviewers, Associate Editors, and Senior Editors reveal in a letter to the Editor-in-Chief any relationships that they have that could be construed as causing a conflict of interest with regard to a manuscript under review. The letter should include a statement of any financial relationships with commercial companies involved with a product under study.

Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the copyright owner of the journal, prior to publication. Once an article is accepted for publication in Clinical Cancer Research, the information therein is embargoed from reporting by the media until the mail date of the issue in which the article appears.

The Editors endorse the principles embodied in the Declaration of Helsinki and expect that all investigations involving humans will have been performed in accordance with these principles. To obtain a copy of the Helsinki Declaration, please contact the World Medical Association, 28, Ave. des Alpes, F-01210, Ferney-Voltaire, France. For animal experimentation reported in the journal, it is expected that investigators will have observed the Interdisciplinary Principles and Guidelines for the Use of Animals in Research, Testing, and Education issued by the New York Academy of Sciences’ Ad Hoc Committee on Animal Research, a copy of which is available for $5.00 from the Marketing Department, New York Academy of Sciences, 2 East 63rd Street, New York, NY 10021-7289. All human and animal studies must have been approved by the investigator’s Institutional Review Board.

Review Process
The review process is conducted as rapidly as possible. Each submitted manuscript is reviewed by at least two experts in the field of investigation. If the authors are invited to submit a revised manuscript for an expedited further review, the revised version must be submitted within three months.

Publication Fees
A page charge of $35 per printed page will be levied on all manuscripts accepted for publication. It is understood at the time of submission that the author(s) agree to pay this charge in the event of publication. Under exceptional circumstances, when no grant or other source of support exists, the author(s) may apply to Dr. Margaret Foti, Director of Publications, AACR Publications Department (see page ii for address) at the time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges.

Procedures for Submission
Submit papers directly to the Deputy Editor or to one of the seven Senior Editors, each of whom is responsible for a particular area of research. The Deputy Editor and the Senior Editors will conduct the review process with the expert assistance of the journal’s Associate Editors, who will correspond with authors about their manuscripts, and will make editorial decisions regarding publication. Papers within the subject areas covered by the Editor-in-Chief, as well as manuscripts that do not pertain to any of the research areas listed, should be submitted to Dr. Mendelsohn. Research areas, mailing addresses, and telephone and fax numbers for the Editor-in-Chief, Deputy Editor, and Senior Editors can be found at the end of these Instructions.

Submit four original sets (not photocopies) of figures along with four copies of the manuscript. If a manuscript is closely related to papers that are in press or have been submitted elsewhere, please provide copies of those papers with your submission. For an original and revised submission, we cannot guarantee that manuscripts and illustrations will be returned to the author.

The letter of submission can suggest the Associate Editors who might serve as reviewers of the manuscript. In addition, we invite authors to provide the names, addresses, and telephone/fax numbers of other potential reviewers who are not current or recent collaborators or advisors in the area under investigation.

Advances in Brief will be reserved for concise, definitive reports of novel observations and discoveries that have unusual importance. A request for consideration for Advances in Brief should be included in the letter of submission. A Minireview is a brief analysis (typically 3-4 printed pages) of a focused, timely research topic, aimed at a multidisciplinary audience. Minireviews and Controversies in Clinical Cancer Research that are submitted or solicited will undergo editorial review. The Editors welcome Letters to the Editor, which will be published if they are determined to be appropriate.

Format
Manuscripts must be written succinctly in clear, grammatical English. Define abbreviations in an inclusive footnote to the text. Double-space on 8 1/2 x 11-inch paper. Dot-matrix printing is not acceptable. The format is as follows:

1. Title page, including title, authors and their institutions, research support, and address plus telephone/fax numbers of the corresponding author;
2. A running title of fewer than 50 characters;
3. Three to five key words that do not appear in the title;
4. Abstract, of not more than 250 words, stating briefly the objectives, methods, results, and conclusions of the study;
5. Text arranged in this order: Introduction, Methods, Results, Discussion, Acknowledgments, References;
6. Footnotes, on a page separate from the text. Designate footnotes consecutively with superscript Arabic numerals;
7. Legends, on pages separate from the text, with descriptive titles and legends that make the data understandable without reference to the text;
8. Figure legends, on pages separate from the text, with descriptive titles and explanations to make the data understandable without reference to the text. Define all symbols and include staining for those where applicable;

References
Include only those articles that have been published or are in press. Unpublished data or personal communications must be cited as footnotes to the text. Personal communications should be substantiated by a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double-spaced.
SAMPLE REFERENCES:

Figures
Provide four original sets of figures (whether line-cut drawings or halftones). Each sorted set should be in a separate labeled envelope, for distribution to reviewers. A typed label placed on the reverse side of each figure should contain the first author’s name, figure number, and an arrow indicating top of figure. Letters and numbers on figures should not be smaller than 6-point or larger than 12-point type. All figures will be published at a width of approximately 3 inches (8 cm) unless the author requests a greater width. Use tissue overlays to indicate important areas of the photographs that must be reproduced with greater fidelity.

Authors are encouraged to submit color figures. The expense of reproducing color photographs must be offset partially by the author. The cost of color reproduction charged to authors is $975 per color figure. Submit color figures on flexible backing.

Proofs
Page proofs must be returned to the office of the American Association for Cancer Research within 24 hours of receipt. Return proofs by overnight mail. Proofs not received by the deadline will be published without the authors’ corrections. Accepted manuscripts are regarded as final copy and should not be altered substantially in proof. Extensive alterations could cause publication delays, and authors will be charged for excessive alterations in proof.

Typesetting Manuscripts from Computer Disks
Clinical Cancer Research requests the submission of disks to expedite production of accepted manuscripts. If your article is accepted for publication, you will receive instructions regarding disk submission. It is the author’s responsibility to ensure that the material on the disk matches the final accepted version of the manuscript.

Research Areas of the Editor-in-Chief, Deputy Editor, and Senior Editors
John Mendelsohn, M.D., Editor-in-Chief
Department of Educational Publishing Services–227
The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard
Houston, TX 77030
Phone: (713) 792-6014; Fax: (713) 792-6016
E-mail: jmendelsohn@notes.mdacc.tmc.edu

Molecular pathology, molecular regulation, drug metabolism, drug sensitivity and resistance, drug interactions

Bruce A. Chabner, M.D.
Department of Hematology/Oncology
Massachusetts General Hospital
Cox Building, Room 640
100 Blossom Street
Boston, MA 02114
Phone: (617) 724-3200; Fax: (617) 724-3166
E-mail: chabner.bruce@mgh.harvard.edu

Clinical pharmacology and pharmacokinetics, drug metabolism, drug sensitivity and resistance, drug interactions

Michael B. Kastan, M.D., Ph.D.
Division of Pharmacology and Experimental Therapeutics
Johns Hopkins University, Ross 345
720 Rutland Avenue
Baltimore, MD 21205
Phone: (410) 614-2747; Fax: (410) 614-4095
E-mail: mbkastan@welchlink.welch.jhu.edu

Cell cycle regulation, cell death

Lance A. Liotta, M.D., Ph.D.
Laboratory of Pathology
National Cancer Institute
Building 10, Room 2A33
National Institutes of Health
10 Center Drive, MSC 1500
Bethesda, MD 20892-1500
Phone: (301) 496-3185; Fax: (301) 402-0043
E-mail: lance@helix.nih.gov

Pathology, metastasis

David Sidransky, M.D.
Otolaryngology/Head & Neck Cancer Research
Johns Hopkins University
818 Ross Research Building
720 Rutland Avenue
Baltimore, MD 21205-2196
Phone: (410) 550-5153; Fax: (410) 614-1411
E-mail: dsidransky@welchlink.welch.jhu.edu

Molecular pathogenesis, molecular correlates

Paul Sondel, M.D., Ph.D.
Departments of Pediatrics, Human Oncology, & Genetics
University of Wisconsin Clinical Science Center
K4/448
600 Highland Avenue
Madison, WI 53792
Phone: (608) 263-9069; Fax: (608) 263-4226
E-mail: pmsondel@facstaff.wisc.edu

Immunotherapy and cytokines—preclinical, and clinical trials

Beverly A. Teicher, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center, DC 0540
Indianapolis, IN 46285
Phone: (317) 276-2739; Fax: (317) 277-3652
E-mail: teicher.beverly_a@lilly.com

Experimental therapeutics, preclinical pharmacology, combined modality regimens, animal therapy models

Jeffrey M. Trent, Ph.D.
Laboratory of Cancer Genetics
National Center for Human Genome Research
National Institutes of Health
Building 49, Room 4A22
49 Convent Drive, MSC 4470
Bethesda, MD 20892-4470
Phone: (301) 402-2023; Fax: (301) 402-2040
E-mail: jretn@nhgrl.nih.gov

Genetics, cytogenetics

For more information, contact:
John Mendelsohn, M.D., Editor-in-Chief, Clinical Cancer Research,
Department of Educational Publishing Services–227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-6014; Fax: (713) 792-6016.

or:
Publications Department, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 South Independence Mall West, Philadelphia, PA 19106-3483. Phone: (215) 440-9300; Fax: (215) 440-9355.
1998 GERTRUDE B. ELION CANCER RESEARCH AWARD

Supported by an Educational Grant from
Glaxo Wellcome Oncology

• This Award was established in honor of Nobel Laureate Dr. Gertrude B. Elion, Scientist Emeritus at Glaxo Wellcome Co. and Past President and Honorary Member of the AACR.

• The Gertrude B. Elion Cancer Research Award is a one-year, $30,000 grant for a scientist in the U.S. or Canada engaged in meritorious basic, clinical, or translational research in cancer etiology, diagnosis, treatment, or prevention at the level of Assistant Professor (not yet tenured).

• The AACR will reimburse the Awardee for travel to the 1998 Annual Meeting in New Orleans, LA, where Dr. Elion will personally present this Award.

Eligibility
Candidates must have completed postdoctoral studies or clinical fellowships not later than July 1 of the Award year, and ordinarily not more than five years earlier. Tenured faculty in academia, federal government employees, and employees of private industry are not eligible for this award. A Candidate need not be a member of the AACR at the time of application, but must be nominated by a Member of the AACR. Associate Members may not be nominators.

Selection Process/Application Deadline
Applications are evaluated by a Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Complete applications must be submitted by December 15, 1997, to be considered for the 1998 Award.

For Further Information/Application Forms
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9372
e-mail: horst@aacr.org
ATTN.: Jenny Anne Horst-Martz
# Statement of Ownership, Management, and Circulation

## 1. Publication Title
Clinical Cancer Research

## 2. Publication No.
10

## 3. Filing Date
10/2/97

## 4. Issue Frequency
Monthly

## 5. No. of Issues Published Annually
11

## 6. Annual Subscription Price
$109.00

### 7. Complete Mailing Address of Known Office of Publication (Street, City, County, State, and ZIP of Post Office)

- **American Association for Cancer Research, Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483**

### 8. Complete Mailing Address of Headquarters or General Business Office of Publisher (Post Office)

- **American Association for Cancer Research, Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483**

### 9. Full Name and Complete Mailing Address of Publisher (Mailing and Managing Editor (If Not Same Person))

- **American Association for Cancer Research, Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483**

### 10. Editor's Name and Complete Mailing Address

- **Dr. John Mendelsohn, Department of Educational Publishing Services - 227, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030**

### 11. Known Bondholders, Mortgagees, and Other Security Holders Owning or Holding 1 Percent or More of Total Amount of Securities, Mortgages, or Other Securities Indicated by Checkmark: None

### 12. For correction by nonprofit organizations authorized to mail at special rates - The purpose, function, and nonprofit status of the organization and the exempt status of its national income tax exemption: Check and 

- **Dr. Margaret Puti, American Association for Cancer Research, Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483**

### 13. Publication Name
Clinical Cancer Research

### 14. Issue Date for Circulation Data Below
October 1997

<table>
<thead>
<tr>
<th>Issue No.</th>
<th>Copies (Post Mailed Free)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5962</td>
<td>5869</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paid and/or Requested Circulation</th>
<th>Sales Through Dealers and Carriers, Street Vendors, and Counter Sales (Not Mailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4468</td>
<td>none</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paid and/or Requested Circulation (Other than Paid, Not Mailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4460</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Paid and/or Requested Circulation (Other than Paid, Not Mailed)</th>
</tr>
</thead>
<tbody>
<tr>
<td>4460</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Free Distribution to Your Reader (Sales, Complete Indicators, and Free)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Free Distribution Outside the Mail (Carriers or Other Mails)</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Distribution (Sum of 10a and 10b)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5962</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Total Paid and/or Requested Circulation (Paid or Not Paid)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1000</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Actual No. Copies of Single Issue Published Not in Filing Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Date of Issue for Post Office Notice</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/30/97</td>
</tr>
</tbody>
</table>

### 15. Notice of Change of Address:

<table>
<thead>
<tr>
<th>Description of Change of Address</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
</tr>
</tbody>
</table>

### 16. Description of New Issues:

<table>
<thead>
<tr>
<th>Description of Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
</tr>
</tbody>
</table>

### 17. Date of Mailing Notice:

<table>
<thead>
<tr>
<th>Date of Mailing Notice</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/10/97</td>
</tr>
</tbody>
</table>

### 18. Code for Certain Circulation Categories:

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td>Direct Mail</td>
</tr>
</tbody>
</table>

### 19. Employer Identification No.:

<table>
<thead>
<tr>
<th>Employer Identification No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>none</td>
</tr>
</tbody>
</table>

### 20. American Association for Cancer Research

- **Philadelphia, PA, 19106-3483**

### 21. Ownership Information:

- **American Association for Cancer Research, Public Ledger Building, Suite 826, 150 S. Independence Mall West, Philadelphia, PA 19106-3483**

### 22. Date of Report:

<table>
<thead>
<tr>
<th>Date of Report</th>
</tr>
</thead>
<tbody>
<tr>
<td>10/30/97</td>
</tr>
</tbody>
</table>

This space contributed as a public service.

A carrot is rich in vitamins A and C, has zero fat, is a good source of fiber, and can help you fight cancer. For more information on fruits and vegetables that can do the same, call 1-800-ACS-2345.

Help us to serve you better.....

**USE YOUR ZIP CODE**

Remember, your zip code provides faster, more direct delivery of your journals. Use it on all correspondence, too.
AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ACTIVE AND
CORRESPONDING MEMBERSHIP

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society of over 13,000 laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage the presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.

Members of the AACR enjoy the following benefits:

1. The privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting;
2. Subscriptions to the Association’s high-quality journals Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates;
3. An advance copy of the Program and Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. Reduced registration rates at annual meetings;
5. Priority notice of small, focussed meetings in the AACR’s exciting series of Special Conferences in Cancer Research;
6. Substantially reduced registration rates for Special Conferences;
7. Opportunities for participation in AACR meetings in North America and abroad with other scientific societies around the world;
8. Receipt of AACR Newsletters and other important announcements;
9. Early notification of and reduced rates for participation in the AACR Employment Register;
10. An up-to-date Membership Directory of over 13,000 member researchers in the cancer field;
11. The professional benefits of the AACR’s public education activities concerning funding for cancer research and press coverage of the latest research findings;
12. The opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators;
13. The facilitation of informal scientific exchange with leading researchers in the cancer field; and
14. Many more ongoing benefits.

QUALIFICATIONS FOR MEMBERSHIP

Active membership in the AACR is open to investigators who live in the Americas. Individuals who have conducted two years of research resulting in peer-reviewed publications relevant to cancer, or who have made substantial contributions to cancer research in an administrative or educational capacity, are eligible. If a candidate has conducted research in an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be submitted as qualifications for membership in lieu of peer-reviewed publications.

Corresponding membership is open to persons who are not residents of the Americas. The qualifications for corresponding membership are the same as those indicated above for active membership. Visiting scientists from outside the Americas who intend to return to their countries of origin by the anticipated time of election should apply for corresponding membership. All other visiting scientists should apply for active membership and transfer to corresponding status upon leaving the Americas.

Graduate and medical students, postdoctoral fellows, and physicians in training who do not yet meet the above qualifications for active or corresponding membership should apply for associate membership. Forms for associate membership are available from the AACR Office.

PROCEDURES FOR APPLICATION

There are three deadlines for the receipt of a membership application: January 1, May 1, and September 1 of each year. The Membership Committee will review all complete applications for active membership that have been received by these deadlines and will submit recommendations on each candidate to the Board of Directors which formally elects all members. The same procedure is followed by the Special Membership Committee which receives applications for corresponding membership. Candidates will be notified according to the following schedule:

<table>
<thead>
<tr>
<th>Receipt of Application</th>
<th>Notification of Candidate</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 1</td>
<td>March</td>
</tr>
<tr>
<td>May 1</td>
<td>July</td>
</tr>
<tr>
<td>September 1</td>
<td>November</td>
</tr>
</tbody>
</table>

A complete application consists of the following material:

1. 6 copies of the form on the opposite side of this page, with all requested information provided.
2. 5 copies of the candidate’s most current curriculum vitae and bibliography.
3. 5 copies of a letter of recommendation from a nominator who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). This letter should describe the candidate’s achievements in laboratory research, clinical investigations, or epidemiological research, and it should affirm that this research adheres to accepted ethical scientific standards. –OR– The nominator may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
4. 5 copies of a letter of recommendation as described in Item 3 above from a seconder who is an active, corresponding, emeritus, or honorary member of the AACR (at least one copy must be a signed, original letter). –OR– The seconder may supply the responses requested at the bottom of the application form in the section entitled “STATEMENT OF SUPPORT” (at least one copy of the form must be the signed original).
5. 5 reprints of each of two publications on which the candidate appears as author. As noted above, evidence of patents developed by the candidate may be submitted in lieu of one or both of the publications. If submitting patents, supply patent number and year awarded.

All material should be collated into five complete sets with the original application form as a covering document and sent to the address given below. Questions regarding procedures for membership application may also be directed to the following address:

Membership Services Department
American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
E-mail: aacrcf@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Candidates should be aware of the following responsibilities of membership in the AACR. Active members must pay annual dues. In 1998 annual dues for active members are $175, $100 of which is designated for AACR journal subscriptions. Newly elected members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rates will receive reimbursement of the unused portion of those subscriptions once their first year’s membership dues are paid in full. Corresponding members are required to pay dues ($90 in 1998) and may, if they wish, subscribe to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at reduced member rates.

Applicants elected in March will be responsible for payment of that year’s dues; applicants elected in July and November will pay dues for the following year. Applicants elected in March and July will be eligible to sponsor an abstract for the next annual meeting. Every effort will be made to afford the same opportunity to applicants elected in November.

Margaret Foti, Ph.D.
Executive Director
APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP

NAME OF CANDIDATE: ___________________ ___________________ ___________________
LAST FIRST M.I. DATE OF BIRTH: ____________

PRESENT POSITION/TITLE: ____________________________

INSTITUTIONAL AFFILIATION: ____________________________

INSTITUTIONAL ADDRESS: ____________________________

(City) ___________________ (State/Province) ___________________ (Country) ___________________ (Postal Code) ___________________

TELEPHONE NUMBER: ____________________________ FAX NUMBER: ____________________________

E-MAIL ADDRESS: ____________________________

PRIMARY FIELD OF RESEARCH (Please check only one):

- Biochemistry and Biophysics
- Biostatistics
- Carcinogenesis
- Cellular Biology and Genetics
- Clinical Investigations
- Endocrinology
- Epidemiology
- Immunology
- Molecular Biology and Genetics
- Preclinical Pharmacology and Experimental Therapeutics
- Virology
- Other: ____________________________

(Please specify)

ACADEMIC DEGREES (Including where and when granted)

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list most recent first)

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

________________________________________________________________________________________

CANDIDATE IS APPLYING FOR (Check one): ___________________ _______________

- ACTIVE
- CORRESPONDING
- MEMBERSHIP

CANDIDATE NOMINATED BY*: ___________________ ___________________ ___________________

CANDIDATE SECONDED BY*: ___________________ ___________________ ___________________

(Please print) (Please print)

STATEMENT OF SUPPORT

Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:

I acknowledge by signing this statement of support that this candidate adheres to accepted ethical scientific standards and has or will make a long-term contribution to cancer research.

__________________________________________ ____________________________
Signature of Nominator* Date Signature of Seconder*

See Guidelines for Application on the reverse side of this form for further instructions.

*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR in good standing.
QUALIFICATIONS FOR MEMBERSHIP

Associate membership is open to graduate students, medical students, postdoctoral fellows, and physicians in training who are following a course of study or who are working in a research program relevant to cancer. Scientists in training who already have a substantial record of publications may wish to apply for active or corresponding membership which confers full benefits of membership.

BENEFITS OF MEMBERSHIP

The American Association for Cancer Research (AACR), a scientific society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowledge among scientists and others dedicated to the cancer problem; to foster research in cancer and related biomedical sciences; to encourage presentation and discussion of new and important observations in the field; to foster public education, science education, and training; and to advance the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world. Associate members of the AACR enjoy the following benefits:

1. the privilege of sponsoring a proffered paper (abstract) for consideration for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, corresponding, emeritus, or honorary member in good standing of the AACR also signs the abstract of the paper in support of the work. (In this instance, the member who cosigns the abstract does not lose his or her own sponsorship privilege);
2. optional subscriptions to the Association’s high-quality journals: Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, and Cancer Epidemiology, Biomarkers & Prevention at reduced member rates; beginning in 1998 associate members will be able to purchase AACR journals for half the price of a regular member subscription;
3. an advance copy of the scientific Program and (if one has been purchased by the associate member) the Proceedings of the American Association for Cancer Research that contains over 4,000 abstracts of proffered papers presented at the annual meeting;
4. the privilege of registering for the annual meeting at the low associate member rate;
5. the privilege of electing an Associate Member Council that organizes programs benefiting associate members and that presents their concerns to the AACR Board of Directors;
6. the opportunity to stand for election to the Associate Member Council;
7. preferred access to the AACR Employment Register;
8. priority notification of events in the AACR’s series of special conferences on timely subjects in the field;
9. substantially reduced registration rates at special conferences;
10. the receipt of AACR newsletters, meeting announcements, and an up-to-date Membership Directory;
11. the opportunity to participate in three Summer Workshops that foster knowledge in the cancer field for young investigators; and
12. the facilitation of informal scientific exchange with leading researchers in the cancer field.

PROCEDURES FOR APPLICATION

Persons wishing to apply for associate membership must use the official application form on the reverse side of these instructions. Each candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the AACR. Three completed copies of the form should be submitted; at least one of these copies must carry the original signatures of both the candidate and the nominator. In addition, the candidate should submit one copy of his or her curriculum vitae. The application form may be submitted to the Association Office at any time.

After review of applications for associate membership, the Executive Director will notify candidates of their election or deferral within one month of the receipt of the application form. A check for one year’s dues payment must accompany the application. Dues for 1998 are $45 for associate members residing in the Americas and $55 for residents of other countries. This fee will be refunded to any candidate deemed to be ineligible for associate membership. Checks should be in U.S. currency, made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the appropriate dues payment to:

Membership Services Department
American Association for Cancer Research
Public Ledger Building. Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
Phone: 215/440-9300
Fax: 215/440-9412
E-mail: aacr@aacr.org

RESPONSIBILITIES OF MEMBERSHIP

Associate members must pay annual dues in an amount to be determined by the AACR Board of Directors. Dues for 1998 have been set at $45 per year for residents of the Americas and $55 for residents of other countries. If an application is submitted by August 31, the accompanying dues payment will be credited to the current year. Candidates submitting applications between September 1 and December 31 may indicate whether they wish their dues payments credited to the current or forthcoming year. Candidates should be aware, however, that associate members may sponsor an abstract for the annual meeting only if their dues for the current year are paid. For example, an associate member submitting an abstract in October 1997 for the forthcoming annual meeting must have paid dues for 1997. Any newly elected associate members of the AACR who have already purchased subscriptions to Cancer Research, Clinical Cancer Research, Cell Growth & Differentiation, or Cancer Epidemiology, Biomarkers & Prevention at the higher, nonmember rate will receive a refund for the unused portion of that subscription upon receipt of their payment for a member’s subscription.

Each Fall the AACR will send to current associate members an invoice for dues for the forthcoming year. Payment of this invoice must be accompanied by a statement signed by the associate member’s current registrar, dean, or department head, verifying the member’s current academic status. The Association’s By-Laws state that dues are payable for each year in advance by January 1 of the year to which they should be applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays dues for 1998 may retain associate membership until December 31, 2002. The Board of Directors may terminate the membership of an associate member whose dues are in arrears for two years.

Margaret Foti, Ph.D.
Executive Director
AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.
Public Ledger Building · Suite 826 · 150 S. Independence Mall West · Philadelphia, PA 19106-3483

APPLICATION FOR ASSOCIATE MEMBERSHIP

NAME OF CANDIDATE: ___________________________  LAST   ___________________________  FIRST   ___________________________  M.I.   ___________________________  DATE OF BIRTH: ___________________________

INSTITUTIONAL AFFILIATION: ___________________________

INSTITUTIONAL ADDRESS: ___________________________

(City) ___________________________  (State/Province) ___________________________  (Country) ___________________________  (Postal Code) ___________________________

TELEPHONE NUMBER: ___________________________  FAX NUMBER: ___________________________

E-MAIL ADDRESS: ___________________________

PRESENT ACADEMIC STATUS/TITLE (Please check only one):

□ Graduate Student  □ Medical Student  □ Physician in Training  □ Postdoctoral Fellow

□ Biochemistry and Biophysics  □ Biostatistics

□ Cellular Biology and Genetics  □ Clinical Investigations

□ Epidemiology  □ Immunology

□ Preclinical Pharmacology and Therapeutics  □ Virology

□ Carcinogenesis  □ Endocrinology  □ Molecular Biology and Genetics  □ Other: ___________________________

(Please specify)

ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________

_________________________________________________________
Guidelines for Submitting Disks to American Association for Cancer Research Publications

The word processing packages that we prefer are as follows:

<table>
<thead>
<tr>
<th>Software Package</th>
<th>Word Processing Packages</th>
</tr>
</thead>
<tbody>
<tr>
<td>MacWrite</td>
<td>WordPerfect (DOS, Windows, and Macintosh)</td>
</tr>
<tr>
<td>Microsoft Word (DOS, Windows, and Macintosh)</td>
<td>XyWrite (DOS and Windows)</td>
</tr>
</tbody>
</table>

Also acceptable:

<table>
<thead>
<tr>
<th>Software Package</th>
<th>Word Processing Packages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ability</td>
<td>Mass 11</td>
</tr>
<tr>
<td>AmiPro</td>
<td>MS Windows Write</td>
</tr>
<tr>
<td>A_s-Ten</td>
<td>MS Works</td>
</tr>
<tr>
<td>Appleworks</td>
<td>MS Works WP Mac</td>
</tr>
<tr>
<td>ArborTeX</td>
<td>Multimate</td>
</tr>
<tr>
<td>ArborText</td>
<td>Multimate Advantage</td>
</tr>
<tr>
<td>ClarisWorks WP</td>
<td>Nibia</td>
</tr>
<tr>
<td>CPT 8000</td>
<td>Nisus (to ASCII file)</td>
</tr>
<tr>
<td>CTOS</td>
<td>Notewriter</td>
</tr>
<tr>
<td>Diablo</td>
<td>Obun</td>
</tr>
<tr>
<td>DisplayWrite</td>
<td>OfficeWriter</td>
</tr>
<tr>
<td>Duet</td>
<td>PC Write</td>
</tr>
<tr>
<td>Einstein</td>
<td>PFS First Choice</td>
</tr>
<tr>
<td>Enable</td>
<td>Professional Write</td>
</tr>
<tr>
<td>EXP</td>
<td>Q&amp;A Write</td>
</tr>
<tr>
<td>Final Word</td>
<td>Quark XPress</td>
</tr>
<tr>
<td>FullWrite</td>
<td>RagTime MS Works</td>
</tr>
<tr>
<td>GemWord Plus</td>
<td>(to ASCII file)</td>
</tr>
<tr>
<td>IBM Writing Assistant</td>
<td>Rich Text Format</td>
</tr>
<tr>
<td>Interleaf</td>
<td>RSG (to ASCII file)</td>
</tr>
<tr>
<td>LATEX</td>
<td>Signature</td>
</tr>
<tr>
<td>Latex</td>
<td>SLiTEx</td>
</tr>
<tr>
<td>Leading Edge</td>
<td>SmartWhere</td>
</tr>
<tr>
<td>Lotus Manuscript</td>
<td>SmartWrite II</td>
</tr>
<tr>
<td>Lotus Write</td>
<td></td>
</tr>
</tbody>
</table>

Software packages that we are unable to translate:

<table>
<thead>
<tr>
<th>Software Package</th>
<th>Word Processing Packages</th>
</tr>
</thead>
<tbody>
<tr>
<td>FrameMaker</td>
<td>Ready, Set, Go</td>
</tr>
<tr>
<td>PageMaker</td>
<td>Scientific Writer</td>
</tr>
</tbody>
</table>

Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.

To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.

PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION.
DISK SUBMISSION FORM

AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.

See reverse for the word processing packages that can be accepted.

File preparation

Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathematical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.

Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.

Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.

Name used to access paper on disk: ________________________________

Name of computer used (e.g., IBM/PS2): __________________________

Operating system and version (e.g., DOS 3.3): ______________________

Word processing program and version (e.g., WordPerfect 5.0): ______

[See reverse for acceptable programs.]

Manuscript number: _____________________________________________

First author: ___________________________________________________

Corresponding author (if different from first author): ____________________

Telephone/FAX numbers: _________________________________________

This form (both sides) may be reproduced.
AACR MINORITY SCHOLAR AWARDS IN CANCER RESEARCH

Supported by a generous grant from the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI)

AACR Minority Scholar Awards in Cancer Research are offered to eligible minority scientists wishing to attend the Annual Meeting and Special Conferences of the American Association for Cancer Research (AACR). The awards are supported by a generous grant from the Comprehensive Minority Biomedical Program of the National Cancer Institute (NCI). Those eligible for these awards are graduate and medical students, physicians-in-training, and postdoctoral students from minority groups considered underrepresented in cancer research by the NCI, i.e., African Americans, Alaskan Natives, Hispanic Americans, Native Americans, and Native Pacific Islanders.

The 89th AACR Annual Meeting will take place March 28 - April 1, 1998, in New Orleans, LA. This year's annual meeting will attract approximately 7,500 scientists from around the world, will provide the latest findings in the most rapidly developing areas of basic, clinical, and translational cancer research, and will feature major presentations from prominent scientists who are making important advances in the field. The deadline for receipt of applications for Minority Scholar Awards for the 89th AACR Annual Meeting is December 1, 1997.

Applications for Special Conference awards are due approximately two months before the date of the meeting. The AACR special conferences on focused topics in cancer research have gained wide recognition as unique opportunities for in-depth discussion of important scientific issues in attractive, informal resort environments. For Special Conferences only, minority faculty at the level of Instructor, Lecturer, or Assistant Professor are also eligible for these awards.

For Further Information:
Ms. Robin E. Felder, Membership Development Coordinator
AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300
FAX: (215) 440-9313
Email: felder@aacr.org
http://www.aacr.org
AMERICAN ASSOCIATION FOR CANCER RESEARCH

1998 RESEARCH FELLOWSHIPS

For Young Scientists at the Postdoctoral or Clinical Fellow Level

- **1998-1999 Research Fellowship in Basic Research:** This Fellowship, sponsored by the AACR, will provide a two-year grant of $30,000 per year to a young scientist in North, Central, or South America engaged in meritorious basic cancer research.

- **1998-1999 Research Fellowship in Clinical/Translational Research:** This Fellowship, sponsored by Amgen, Inc., will provide a two-year grant of $30,000 per year to a young scientist in North, Central, or South America engaged in meritorious clinical or translational cancer research.

- **1998-1999 Research Fellowship in Clinical Research:** This Fellowship, sponsored by Bristol-Myers Squibb Oncology, will provide a two-year grant of $30,000 per year to a young scientist in North, Central, or South America engaged in meritorious clinical cancer research.

- **1998-1999 Research Fellowship in Prevention Research:** This Fellowship, sponsored by the Cancer Research Foundation of America, will provide a two-year grant of $30,000 per year to a young scientist in North, Central, or South America engaged in meritorious cancer prevention research.

- **1998 Research Fellowships in Basic Research:** Two Fellowships, sponsored by the Sidney Kimmel Foundation for Cancer Research and Hoechst Marion Roussel, will each provide a one-year grant of $30,000 to a young scientist in North, Central, or South America engaged in meritorious basic cancer research.

**Eligibility/Selection Process**

Candidates must have completed the M.D., Ph.D., or other doctoral degree. Candidates must currently be a postdoctoral or clinical research fellow and must have been a fellow for at least two years but not more than five years prior to the year of the award. Academic faculty holding the rank of assistant professor or higher, graduate or medical students, medical residents, permanent government employees, employees of private industry, and individuals who will receive fellowships from similar programs during the award year are not eligible. A candidate need not be a member of the AACR at the time of application, but he or she must be nominated by an AACR Member, and non-members must submit an acceptable application for membership with the fellowship application. Associate Members may not be nominators. Applications will receive careful scientific evaluation by a prestigious, multidisciplinary Committee consisting of AACR Members who are experts in basic, clinical, and translational cancer research. Applications must be submitted in complete form by January 15, 1998.

**For Further Information/Application Forms**

AMERICAN ASSOCIATION FOR CANCER RESEARCH
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
Telephone: (215) 440-9300 • FAX: (215) 440-9372
E-mail: horst@aacr.org